MedTrace Logo

Clinical Application of Multi-modal Sentinel Lymph Node Staining Method in Breast Cancer Patients After Neoadjuvant Chemotherapy

NCT06212440 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 348

Last updated 2025-03-13

No results posted yet for this study

Summary

This clinical trial aimed to confirm the effectiveness of sentinel lymph node surgery by determining the lymph node identification rate using multimodal sentinel lymph node marker methods in patients with advanced breast cancer undergoing neoadjuvant chemotherapy (NAC).

Conditions

  • Sentinel Lymph Node Biopsy
  • Neoadjuvant Therapy
  • Breast Neoplasm

Interventions

DIAGNOSTIC_TEST

Radioactive Isotope (RI) Mapping

Administered via peritumoral or subareolar injection for sentinel lymph node detection.

DIAGNOSTIC_TEST

Indocyanine Green Fluorescence (ICG-F) Mapping

Administered via peritumoral or subareolar injection, detected using near-infrared fluorescence imaging.

DIAGNOSTIC_TEST

Vital Dye Mapping

Administered via peritumoral or subareolar injection for intraoperative visualization of lymphatic drainage pathways.

Sponsors & Collaborators

  • National Cancer Center, Korea

    lead OTHER_GOV

Principal Investigators

  • Seeyoun Lee, Doctor · National Cancer Center, Korea

Study Design

Allocation
RANDOMIZED
Purpose
DIAGNOSTIC
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
20 Years
Sex
FEMALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2021-05-04
Primary Completion
2024-08-14
Completion
2024-10-02

Countries

  • South Korea

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06212440 on ClinicalTrials.gov